|
|
|
|
| LEADER |
01756nam a2200301 u 4500 |
| 001 |
EB001872261 |
| 003 |
EBX01000000000000001035632 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Dexamethasone (Ozurdex) (Allergan, Inc.)
|h Elektronische Ressource
|b indication for the treatment of adult patients with diabetic macular edema who are pseudophakic
|
| 246 |
3 |
1 |
|a Dexamethasone (Ozurdex) (Allergan, Inc.)
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, 2018 Nov
|
| 300 |
|
|
|a 1 online resource
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Macular Edema / drug therapy
|
| 653 |
|
|
|a Dexamethasone / therapeutic use
|
| 653 |
|
|
|a Diabetic Retinopathy / drug therapy
|
| 653 |
|
|
|a Pseudophakia
|
| 653 |
|
|
|a Treatment Outcome
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK539255
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Dexamethasone (Ozurdex) has a Health Canada-approved indication for the treatment of macular edema following central retinal vein occlusion, the treatment of noninfectious uveitis affecting the posterior segment of the eye, and for the treatment of adult patients with diabetic macular edema (DME) who are pseudophakic. The objective of this review is to perform a systematic review of the beneficial and harmful effects of dexamethasone 700 mcg intravitreal injection for the treatment of adults with DME who are pseudophakic
|